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Introduction: We aimed to examine the longitudinal association between
Myasthenia Gravis (MG) clinical severity and concentration of acetylcholine
receptor (AChR)-antibodies to evaluate if AChR-antibody variations correlate to
disease severity. A positive AChR-antibody test is specific for MG.
Material and Methods: All patients from western Norway who had two or more
AChR- antibody tests in the period 1983–2013 were identified. The Myasthenia
Gravis Foundation of America (MGFA) Clinical Classification was used to grade
disease development. Multiple ordinal logistic regression analysis was used to
estimate a possible predictive effect for AChR-antibody concentration on MGFA
classification result.
Results: In 67 patients two or more AChR-antibody tests with a corresponding
MGFA-score were performed, with a total of 309 tests. 56 patients were treated with
immunosuppressive drugs and 11 by pyridostigmine only. There was a positive
association between concentration of AChR-antibodies and longitudinal MGFA-
score for the subgroup with immunosuppressive treatment, but not for those treated
with pyridostigmine only. This association between AChR-antibody concentration
and MGFA score declined with increasing time since onset (p50.005 for the
interaction of group6time6concentration).
Conclusions: For MG patients with immunosuppressive treatment, repeated
AChR-antibody measurements give information about clinical development, and
can therefore be of support in therapeutic decisions.
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Introduction
Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with an
incidence of 7–16 per million per year [1, 2]. The disorder is caused by antibodies
binding to components in the neuromuscular junction [3], impairing neuro-
muscular transmission. In 85 percent of cases, the antibodies bind to the
postsynaptic nicotinic acetylcholine receptor (AChR), termed anti-AChR MG [4].
The antibodies reduce the number of functional AChR by cross-binding the
receptors with increased degradation [5, 6], lysis of postsynaptic membrane by
complement activation [7], and by direct blockade [8]. In some patients, AChR-
antibodies are detectable in a sensitive cell-based assay only [9]. 5–8 percent of the
anti-AChR negative MG patients, have MG induced by antibodies to muscle-
specific tyrosine kinase (MuSK) [10, 11], and in 3–9 percent to low-density
lipoprotein receptor-related protein 4 (LRP4) [12–14].
The loss of functional AChRs causes fluctuating skeletal muscle weakness,
fatigability, and improvement by rest. Ptosis and diplopia are frequent onset
symptoms [15, 16]. Respiratory muscles can also be affected and lead to
myasthenic crisis [17]. The fluctuation during the day and the variable
predominance of affected muscle groups makes it difficult to score these patients
for symptom severity. The Myasthenia Gravis Foundation of America (MGFA)
has developed a uniformly accepted grading system [18] (Table 1), mainly
developed for clinical trials, but also widely used in the clinical management of
MG patients.
Presence of AChR-antibodies is nearly 100 percent specific for MG [19]. The
concentration of AChR-antibodies does not correlate with clinical status between
individuals [20, 21]. Patients with mild disease may have high concentrations of
AChR- antibodies, and vice versa. The association between intra-individual
AChR- antibody concentration and clinical status is not clear. Studies evaluating
this association are inconsistent, data are scarce, and most of the studies were
conducted in the 1980s. There is a need for a prognostic marker to support
therapeutic decisions regarding the intensity of the immunosuppressive therapy.
An objective marker, such as AChR-antibody concentration, if associated with
clinical state, should allow a more precise and consistent MG treatment. The
number of repeated AChR-antibody tests taken of patients with a confirmed MG
diagnosis increases markedly in some countries [1, 22]. This indicates that AChR-
antibody concentration is widely used to evaluate clinical status and prognosis
even though the scientific evidence for this practice is lacking.
A recent study found a weak correlation between change in AChR-antibody
concentration and clinical status [23]. They concluded that concentration of
AChR-antibodies might be useful as a marker for non-response or inadequate
immunotherapy. The study concluded nevertheless not to recommend AChR-
antibodies as a general follow-up biomarker, mainly because the concentration of
AChR-antibodies fell also in most of the patients who did not improve.
In our study, we examined the association between concentration of AChR-
antibodies and MG clinical state in individual patients from a national cohort
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over time to assess whether repeated antibody measurements have any predictive
value for therapeutic decisions.
Materials and Methods
Ethics statement
Written consents were only obtained from patients alive as the Regional ethics
committee allowed us to use patient data from deceased patients’ next of kin
without any further consent. The study was approved by the regional ethics
committee (REK Vest, reference 2012/1480).
Study population
Approximately 15 000 AChR- ntibody samples were analysed 1983–2013 at
Haukeland University Hospital, Bergen, Norway. Patient information for all the
tests included name, date of birth, name of referring hospital or doctor, and date
of sample acquisition. All patients registered as living in the three counties
Rogaland, Hordaland, and Sogn og Fjordane (western Norway) with two or more
AChR-antibody tests were included in this study. Western Norway had 269 anti-
AChR MG patients examined in the included time period. A total of 185 of these
had more than one AChR-antibody test performed. Eighty-five patients were
deceased and still included; 98 patients were alive on 1 November 2012 (study
start), and two patients were impossible to trace. The patients alive were contacted
Table 1. Myasthenia Gravis Foundation of America Clinical Classification [18].
Class Clinical symptoms
I Any ocular weakness
II Mild Weakness. May also have ocular muscle weakness of any severity
II A Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of
oropharyngeal, respiratory muscles or both
II B Predominantly affecting ororpharyngeal, respiratory muscles, or both. May also have lesser or
equal involvement of limb, axial muscles or both
III Moderate weakness affecting other than ocular muscles. May also have ocular muscle
weakness of any severity
III A Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of
oropharyngeal, respiratory muscles or both
III B Predominantly affecting ororpharyngeal, respiratory muscles, or both. May also have lesser or
equal involvement of limb, axial muscles or both
IV Severe weakness affecting other than ocular muscles. May also have ocular muscle weakness
of any severity
IV A Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of
oropharyngeal, respiratory muscles or both
IV B Predominantly affecting ororpharyngeal, respiratory muscles, or both. May also have lesser or
equal involvement of limb, axial muscles or both
V Defined by intubation, with or without mechanical ventilation, except when employed during
routine postoperative management
doi:10.1371/journal.pone.0114060.t001
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in writing, informed and given consent form to sign. Signed consent was obtained
from 82 patients (positive response rate 84 percent). Twentyfour of the deceased
and 43 of those still alive had two or more AChR- antibody tests combined with a
MGFA Clinical Classification. These 67 patients constituted our total sample.
Fifty-six of the included patients had immunosuppressive treatment (immuno-
suppressive MG group), whereas 11 were treated with pyridostigmine only
(pyridostigmine MG group).
Twenty-three patients had early-onset MG (debut ,50 years), 26 had late-onset
MG (debut .50 years). Fourteen had a thymoma, and five patients had pure
ocular MG. Four patients (6.0%) had experienced a myasthenic crisis. Thirty-one
patients were thymectomised.
AChR-antibody assay
All AChR-antibody assays for patients from Western Norway were performed in a
single laboratory at Haukeland University Hospital during the whole period. In
the period 1983–1994, human striated muscle obtained at the Department of
Surgery was used as antigen and AChR- antibody concentrations were given in
arbitrary units (U/L). From 1994, a commercial kit has been used using AChR
from human muscles as antigen in a radioimmunoassay (IBL-Hamburg GmbH,
Germany). Concentrations are given in nmol/L. All samples with a concentration
.0.4 nmol/L were defined as AChR-antibody positive [24]. All patient serum
samples were stored at 4 C̊ and analysed within 3 weeks. Four times a year, the
laboratory participates in a control trial assessment to ensure the analytic quality.
In the present study, only tests analysed after 1994 were included. Time for MG-
onset was in this study defined as date of first positive AChR-antibody sample.
The AChR-antibody sample was defined as valid if obtained one month before or
after an MGFA-score [25].
MGFA Clinical Classification
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification [18]
was used to evaluate the clinical status of the patients (Table 1). This classification
was designed to identify MG subgroups with distinct clinical features or severity of
the disease that could indicate different prognoses or responses to therapy. MGFA
Clinical Classification was developed to accommodate the need for a universally
accepted classification, and divides MG into five classes. In this study we did not
subdivide into A or B, according to localisation of weakness. Patients with no
symptoms were scored as 0. The MGFA-score was derived from structured notes
in the neurological journal that included distinct clinical features of ocular-, limb-
and/or bulbar weakness. We then identified all the AChR-antibody tests and
linked the test with the corresponding MGFA-score. The MGFA Clinical
Classification was therefore performed blinded to AChR-antibody concentration.
Initially, and according to this assessment of the patients, two observers
AChR-Antibodies and Association to Clinical MG Development
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independently classified the first medical note of 33 randomly picked patients
[26].
Statistics
Descriptive statistics are reported as mean, median, standard deviation, minimum
and maximum as appropriate. Inter-examiner agreement of the MGFA-score was
quantified using the kappa coefficient and tested with McNemar-Bowker’s test.
Clinical evaluations and AChR- antibody measurements were done at irregular
time intervals for each patient. Therefore time since first test was analysed both as
a continuous variable and divided into four quartiles for each patient. The first-
quartile comprised 0.24 years (0–3 months), the second- quartile comprised 0.24–
1.85 years (3–19 months), the third-quartile comprised 1.85 to 4.93 years (19–37
months), and the fourth-quartile comprised the rest of the time period (37
months-18 years). In the quartile model, the variation within each quartile was
missed, but associations over time with regular intervals became more precisely
elucidated. Multiple ordinal logistic regression using generalised estimating
equations, correcting for repeated measures in the same individuals (intra-
individual analyses) by assuming an exchangeable correlation structure, was used
to estimate a possible predictive effect of AChR- antibody concentration (nmol/L)
and time since onset on MGFA-score [27]. We especially tested for a change of
effect of AChR-antibody concentration on MGFA-score over time since onset was
different for the pyridostigmine and the immunosuppressed MG groups (test of
time6AChR6MG group interaction). Results are reported as odds ratios (OR)
and 95 percent confidence intervals (CI). SPSS 21 was used for all statistical
analyses.
Results
A total of 67 patients were included with 309 measurements of AChR- antibodies
and with a corresponding MGFA -score. The immunosuppressed MG group
constituted 56 of the 67 patients, with 272 antibody measurements and a
corresponding MGFA-score. The pyridostigmine MG group constituted 11
patients, and with 37 AChR- antibody measurements with a corresponding
MGFA-score. The number of measurements for each patient ranged from 2 to 13,
with an average of 4.5 (Table 2). Mean MGFA-score was 2.0 for the
immunosuppressed MG group and 1.9 for the pyridostigmine MG group
(Table 3). The overall median MGFA-score was 2 in the first three quartiles and 1
in the fourth quartile, with the mean value decreasing from 2.0 to 1.3 over time
(Table 4). Four patients had experienced a myasthenic crisis, three females and
one male, all with late-onset MG. For all the 309 AChR-antibody tests from the 67
included MG patients, the concentrations ranged from 0 to .300 nmol/L, with a
mean value between 19.1 and 27.2 nmol/L (Table 4). The mean concentration did
not differ in the three first quartiles, but was decreased in the fourth (F-test
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p-value50.020 from mixed linear regression accounting for correlation between
repeated measures within patients). The median AChR- antibody concentration
was 14.4 for the immunosuppressed MG group, and 10.8 for pyridostigmine MG
group. Inter-examiner agreement for MGFA was Kappa (K) 0.84 (almost perfect)
(standard error (SE) 0.74, 95% confidence interval (CI): (0.70–0.99) [28]. Total
percent of agreement was 88 percent. McNemar-Bowker’s test showed no
disagreement symmetry (p50.368). A high MGFA-score was more probable in the
first quartile, and the score decreased significantly with increasing time since onset
Table 2. Distribution of number of AChR-antibody measurements with a corresponding MGFA-score in 67
patients 1983–2013.














Table 3. Demographic statistics at first antibody test of all MG patients (n567) with two or more positive AChR-antibody tests registered as living in western
Norway 1983–2013 according to immunosuppressive (n556) and pyridostigmine (n511) therapy.
Variables Immunosuppression Pyridostigmine only P-value
Age, mean (SD) 55.8 (17.9) 49.1 (24.1) 0.31a
Sex, n (%) 0.33b
Women 31 (55.4) 4 (36.4)
Men 25 (44.6) 7 (63.6)
Subgroup, n (%) 0.18b
Early-onset 16 (28.6) 6 (54.5)
Late-onset 23 (41.1) 4 (36.4)
Ocular 3 (5.4) 1 (9.1)
Thymoma 14 (25.0) 0 (0.0)
AChR-ab concentration, median
(IQR)
14.4 (24.8) 10.8 (18.5) 0.55a
MGFA-score, mean (SD) 2.0 (1.4) 1.9 (1.2) 0.90a
Abbreviations: MG: Myasthenia gravis; SD: standard deviation; AChR: acetylcholine receptor; ab: antibody; MGFA: Myasthenia Gravis Foundation of
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(Wald-p50.036 from unadjusted ordinal regression of MGFA on time quartiles).
This illustrates how well-treated patients with MG improve over time. The
immunosuppressed and the pyridostigmine MG groups differed significantly
regarding the association between AChR-antibody concentration and MGFA-
score over time since onset (three-way interaction in ordinal logistic regression
Wald-p50.005). After further adjustment for gender, subclass and thymectomy
this interaction was only marginally significant (p50.059). Results are given in
Table 5 after some parameterization. Analyses with time since onset as a
continuous variable gave p50.595 for the three-way interaction when we did not
adjust for other variables, probably because the interaction is not linear by linear
for the two continuous variables. When adjusting for the other variables the
analyses never converged. We then analysed the two MG groups separately giving
the following results.
Immunosuppressed MG group
There was an association between changes in longitudinal AChR-antibody
concentration and changes in MGFA-score in individual immunosuppressed MG
patients. This was demonstrated by using both time since onset and AChR-
antibody concentration as continuous variables. If the concentration of AChR-
antibodies increased by 10 nmol/L, it was 10 percent more likely that the MGFA-
score would worsen (common OR: 1.13, 95%: (1.06, 1.20). This association was
also demonstrated by dividing time into four quartiles, showing no significant
interaction between AChR- antibody concentration and MGFA-score on group
level (Wald-p50.349). This indicates an effect of AChR-antibody concentration
on the MGFA- score for the whole study period, though not significant for the last
quartile (Table 5).
Pyridostigmine MG group
In the group treated with pyridostigmine only, a positive association between
AChR-antibody concentration and MGFA-score was not significant. Moreover,
the effect of AChR-antibody concentration on MGFA-score also declined after the
Table 4. Descriptive statistics for MGFA-score (1–5) and AChR-antibody concentration (nmol/L) in each quartile of time since onset for 309 tests of 67 MG




tests Median Mean SD Min Max Median Mean SD Min Max
1st quartile 77 2 2.0 1.3 0 5 12.0 26.6 46.1 0 .300
2nd quartile 78 2 1.4 1.1 0 4 12.6 27.2 48.1 0 291
3rd quartile 77 2 1.4 1.0 0 4 10.4 26.9 44.7 0 228
4th quartile 77 1 1.3 1.0 0 5 6.5 19.1 33.3 0 208
Abbreviations: MGFA: Myasthenia Gravis Foundation of America; AChR: acetylcholine receptor; MG: Myasthenia gravis; SD: standard deviation.
a)1st quartile: 0–3 months; 2nd quartile: 3–19 months; 3rd quartile: 19–37 months; 4th quartile: 37 months–21 years.
doi:10.1371/journal.pone.0114060.t004
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three first months (OR: from 1.05 in second quartile to 0.23 in the fourth quartile)
when time since onset increased (Table 5). The declining effect of AChR-antibody
concentration on MGFA- score over time was also demonstrated by using both
time since onset and AChR- antibody concentration as continuous variables
showing the significant interaction between the two (Wald-p50.033).
An interaction between AChR-antibody concentration and time since onset was
neither found significant in the immunosuppressed MG group separately, nor in
the pyridostigmine MG group. However, the overall analysis showed that they
were statistically significant from each other. This means that there is a time-
changing effect of AChR-antibody concentration on MGFA-score in both or one
of the two groups, and we believe it to be most likely with such an effect in the
immunosuppressed MG group.
Discussion
There was an association between AChR-antibody concentration and MGFA-
score when tested longitudinally in individual immunosuppressed MG patients
and over many years. This indicates that repetitive determinations of AChR-
antibody concentration can predict the clinical state for this group. As a valid
biomarker, AChR-antibody tests probably reflect the degree of drug response and
may help in decisions whether the clinician should modify or keep the
immunosuppressive treatment unchanged regarding drug and drug dose. The
clinical evaluation of MG disease status involves complex constructs of objective
signs and subjective symptoms. For the past years, there has been put efforts into
developing rating scales to evaluate the clinic in a more systematic way, but it is
complicated to assess MG even with scales designed for this disorder [18, 29].
Table 5. The effects of AChR-antibody concentrationa) on MGFA classification according to medication group and time since onset based on multiple ordinal
logistic regression of 67 MG patients at Haukeland University Hospital, Bergen, Norway from 1983–2013.
Medication group Odds ratios 95% CI
Pyridostigmine MG group (11 patients)b)
1st time quartile 0.03 (0.00, 1.25)
2nd time quartile 1.05 (0.65, 1.70)
3rd time quartile 0.69 (0.39, 1.22)
4th time quartile 0.23 (0.07, 0.71)
Immunosuppressed MG group (56 patients)c) Odds ratios 95% CI
1st time quartile 4.10 (1.30,12.95)
2nd time quartile 2.41 (1.11, 5.20)
3rd time quartile 3.91 (1.71, 8.91)
4th time quartile 2.48 (0.52,11.94)
Abbreviations: AChR: Acetylcholine receptor; MGFA: Myasthenia gravis Foundation of America (1–5); MG: Myasthenia gravis; CI: Confidence interval.
a)Odds ratio per 100 nmol/L.
b)Patients treated with pyridostigmine only.
c)Patients treated with immunosuppressive drugs.
doi:10.1371/journal.pone.0114060.t005
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AChR-antibody testing should contribute in assessing the status of the patient.
The association between MGFA-score and changes in AChR-antibody concen-
tration was no longer significant after three years, probably due to a more stable
disease after long-term immunosuppression. MG patients in this study improved
over time, in line with previous studies [17, 30]. Only four patients (6%)
underwent a myasthenic crisis, which is lower than expected [17, 31].
For the pyridostigmine MG group, there was no association between MGFA-
score and concentration of AChR-antibodies for the first three quartiles. For the
fourth quartile of the follow-up period, there was an association, which we,
however, judge as a spurious effect. This indicates that repeated AChR-antibody
tests are useful in monitoring MG patients on immunosuppressive treatment, but
have less value in the follow-up of patients treated symptomatically with
pyridostigmine only. The lack of association was demonstrated by a declining
correlation between concentration of AChR-antibodies and MGFA-score with
increasing time since onset. The difference between the immunosuppressed and
the pyridostigmine MG-groups stresses the fact that the two groups should be
handled differently regarding frequency of AChR-antibody testing and inter-
pretation of the concentration. The reason why these two groups differ is probably
due to the effect of immunosuppressive drugs on the autoantibody production.
Corticosteroids, azathioprine and cyclosporine inhibit T-cell proliferation via
several mechanisms, and thereby inhibit activation of B- cells and reduce the
concentration of circulating AChR-antibodies. Cyclophosphamide and rituximab
suppress B-cell activation and synthesis [32–35]. The AChR-antibodies destruct
the muscle endplate, and a reduction of circulating AChR-antibodies improves
the signaling between nerve and muscle [36], and thereby the MG symptoms.
The patients in this study constitute a population-based and representative
cohort [1], with a very high rate of participation. However, only patients having
two or more AChR-antibody concentration tests performed were included, and
this may represent a selection bias. Patients with only one test may have had a
stable disease in remission, and with less immunosuppressive treatment. All
AChR-antibody samples were analysed at the same laboratory with the same
commercial antibody assay method. This makes comparisons over time reliable.
We used the MGFA Clinical Classification [18] as a score to identify the course
of the disease in the individual patient. There is an inherent imprecision when
distinguishing between mild, moderate and severe muscle weakness. However, we
found the MGFA- scoring suitable, confirmed by the validation. The near perfect
validation result, outweighs to some extent the lack of prospective design. The
classification is not sensitive to small changes due to symptom fluctuations during
the day. For this study, it was important that the score was based on more robust
and long-term clinical development.
This retrospective blinded and validated long- term follow- up study found that
repeated AChR-antibody measurements are valuable to monitor response to
immunosuppressive treatment in individual MG patients, and can be a support
for therapeutic decisions.
AChR-Antibodies and Association to Clinical MG Development
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